Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor–Expressing Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
Clin. Breast Cancer 2022 Apr 01;22(3)269-278, DA Yardley, RR Young, KB Adelson, AL Silber, JE Najera, DB Daniel, N Peacock, L Finney, SJ Hoekstra, M Shastry, JD Hainsworth, HA BurrisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.